Franko - India - Drugs Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 23-10-2024
- Revenue 241.84%
(FY 2023)
- Profit 204.83%
(FY 2023)
- Ebitda 564.93%
(FY 2023)
- Net Worth 399.78%
(FY 2023)
- Total Assets 211.78%
(FY 2023)
About Franko - India - Drugs Formulations
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M.
Manisha Goyal and Saurabh Agarwal serve as directors at the Company.
- CIN/LLPIN
U24299RJ2019PTC064070
- Company No.
064070
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Feb 2019
- Date of AGM
19 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Franko - India - Drugs Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manisha Goyal  | Director | 15-Nov-2019 | Current |
| Saurabh Agarwal | Director | 21-Feb-2019 | Current |
Financial Performance of Franko - India - Drugs Formulations.
Franko - India - Drugs Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 241.84% increase. The company also saw a substantial improvement in profitability, with a 204.83% increase in profit. The company's net worth Soared by an impressive increase of 399.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Franko - India - Drugs Formulations?
In 2023, Franko - India - Drugs Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Laurence Healthcare Private LimitedActive 6 years 11 monthsManisha Goyal and Saurabh Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Oct 2022 | ₹1.50 M | Open |
How Many Employees Work at Franko - India - Drugs Formulations?
Unlock and access historical data on people associated with Franko - India - Drugs Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Franko - India - Drugs Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Franko - India - Drugs Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
